-20℃ 3 years powder
-80℃ 2 years in solvent
KCC-07 is a selective, potent and brain-penetrant inhibitor of methyl-CpG-binding domain protein 2(MBD2) with anticancer activity. KCC-07 prevents binding of MBD2 to methylated DNA and activates brain specific angiogenesis inhibitor 1 (BAI1) inducing anti-proliferative BAI1/p53/p21 signaling.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | In stock | 209.00 | |
25 mg | In stock | 625.00 |
Description | KCC-07 is a selective, potent and brain-penetrant inhibitor of methyl-CpG-binding domain protein 2(MBD2) with anticancer activity. KCC-07 prevents binding of MBD2 to methylated DNA and activates brain specific angiogenesis inhibitor 1 (BAI1) inducing anti-proliferative BAI1/p53/p21 signaling. |
Targets&IC50 | MBD2 (methyl-CpG-binding domain protein 2), Others, |
Cell Research |
KCC-07 treatment Medulloblastomas (MB) cells, Concentration with 10 μM and Incubation Time with 72 hours
|
Appearance | solid |
Molecular Weight | 269.32 |
Formula | C14H11N3OS |
CAS No. | 315702-75-1 |
-20℃ 3 years powder
-80℃ 2 years in solvent
( < 1 mg/ml refers to the product slightly soluble or insoluble )
Safe and effective drug dosing is necessary, regardless of its purpose of administration. Learn More
bottom
Answers to questions you may have can be found in the Inhibitor Handling Instructions. Topics include how to prepare stock solutions, how to store Products, and issues that need special attention for cell-based assays and animal experiments.